The activation of T cells requires t w o distinct signals. One signal involves interaction of the antigen-specific T-cell receptor with major histocompatibility complex molecules plus antigenic peptide; a second signal, which is antigen nonspecific, is the interaction of CD28 with its natural ligands B7-1 and B7-2lB70. CD28 is expressed on 80% of T cells, is upregulated after activation, and binds t o B7 genefamily members, found on antigen-presenting cells. Because of our interest in the immunologic basis of benign and malignant T-cell-mediated disorders of the skin, we investigated the cellular distribution of CD28 and B7 family members in lesions of psoriasis and mycosis fungoides. By immunostaining cryostat sections of skin, CD28 was found t o be expressed on virtually all lymphocytes in the epidermis and dermis of both skin diseases. Surprisingly, 87-1 was also found to be expressed on virtually all lymphocytes in the epidermis and dermis of both skin diseases. B7-1 expression was confirmed on CD3+ T lymphocytes using flow cytometry of single cell suspensions of fresh, unfixed psoriatic lesional CTIVATION OF RESTING T lymphocytes usually requires at least two distinct signals. The first signal is interaction of the antigen-specific T-cell receptor (TCR) with class I1 major histocompatibility complex (MHC) molecules and antigenic peptides; whereas the second signal involves antigen-nonspecific "costimulation," generally delivered by antigen-presenting cells (APCs) of hematopoietic origin.' Several molecules have been proposed to provide this costimulatory signal, the best characterized of which is the CD28 molecule expressed on T cells. Several related CD28-ligands, B7-I, B7-24370, and B7-3/BB-I have been described, and are found on APCs."' Our recent demonstration that the majority of T cells in psoriatic lesions express CD28 was not ~urprising,~ because 60% to 80% of peripheral blood (PB) T cells express CD28.' It is also known that during Tcell activation CD28 expression is increased.' When psoriatic lesions were further investigated using several different monoclonal antibodies (MoAbs). it was observed that keratinocytes stained with anti-BB-l MoAbs (now known to bind to B7-3/BB-I), but not with anti-B7-1 M o A l~s .~ As a follow-up to these studies, we recently immunostained skin samples using a commercially available MoAb against B7-1. We were surprised to observe that this MoAb stained the vast majority of T cells in both epidermal and tissue. To exclude the possibility that this result was caused by a second reagent contaminating the monoclonal antibody (MoAb) preparation, two different lots were used, and the MoAb was absorbed onto Chinese hamster ovary (CHO) transfectants expressing 87-1, or vector-only transfected CH0 cells. These procedures confirmed that a 87-1 -like epitope was being recognized on psoriatic lesional T cells. In contrast t o 87-1 expression on lymphocytes, B7-3, as defined by anti-BB-l MoAb reactivity, was found primarily on epidermal keratinocytes in both skin diseases and was not found on T cells. These results indicate that within t w o common skin disorders, lesional T cells accumulate in the dermis and epidermis, which express B7-1. Such expression may permit self-costimulation involving the CD28-mediated activation pathway, and thereby contribute to the ongoing T-cell proliferation present in these chronic, benign, and malignant skin diseases. 6 1994 by The American Society of Hematology.
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dermal compartments in psoriatic lesions, as well as in cutaneous lesions obtained from patients with cutaneous T-cell lymphoma (mycosis fungoides). Immunostaining of the majority of skin-seeking T cells was unexpected because B7-l has been reported not to be expressed by circulating PB T cells; although it can be upregulated on blood-derived Tcells after activation in vitro."'." When this MoAb was preabsorbed by incubating with Chinese hamster ovary (CHO) cells transfected with a full-length B7-1 cDNA, all staining was abolished, thus indicating that this result was not caused by a second reagent contaminating the MoAb preparation. but that the anti-B7-l MoAb was also binding to the T cells. These data indicate that T-cell expression of B7-I can occur during T-cell activation in vivo, at sites of cutaneous inflammation or neoplasia.
MATERIALS AND METHODS
Clinicul sumples. Punch biopsies ( 3 mm) were obtained from tive untreated psoriatic plaques and four untreated plaques of mycosis fungoides. Each biopsy sample was derived from a different patient after obtaining informed consent. PB samples were obtained by venipuncture and collected in EDTA-containing syringes from normal healthy adult volunteers. Mononuclear cells were isolated from the Ficoll-Hypaque interface after centrifugation. Highly puntied resting T cells were further enriched from these interface cells by vigorous negative selection using a cocktail of MoAbs against B cells, monocytes, natural killer cells, and activated (ie, HLA-DR') T cells, together with magnetic beads as previously described." These T cells were greater than 98% CD3+, lacked HLA-DR. and did not proliferate in response to phytohemagglutinin A (PHA, I O pg/mL). Dermal mononuclear cells were also obtained from psoriatic lesions by keratome sampling of untreated lesions and isolating lymphocytes and dendritic cells as previously described.'' Briefly, the epidermis is separated from dermis using dispase, and the dermal fragments minced and placed in culture medium ( properties using a flow cytometer (see below). All cells were maintained in a humidified incubator with 5% CO2 at 37°C. fmrnunoabsorption studies. To verify that the MoAb against B7-1, L307.4, recognized the B7-1 antigen, C H 0 cells transfected with a full-length B7-1 cDNA (gift of P. Linsley) were stained. The B7-1 transfectants, but not vector-only transfected cells were strongly positive using the MoAb L307.4. Moreover, serial absorption of the anti-B7 MoAb by the CHO-B7-I transfected cells showed proportional decreases after repetitive cycles of coincubation, until there was essentially no significant immunoreactivity of the anti-B7-l MoAb using fresh CHO-B7-1 transfected cells (see Fig 1) . The immunoabsorption was performed by sequentially mixing 1 mL of the anti-B7-1 (IO pg/mL) with lo7 CHO-B7-l transfected cells, or vector-only transfected CH0 cells, for 1 hour. After this coincubation, the cells were pelleted and the MoAb in the Supernatant reexposed to a fresh batch of transfected cells, and the process repeated a total of four times.
Flow cytometry analysis. Between 5 X IO4 to 5 X lo5 T cells were stained with a primary MoAb, and these primary MoAbs detected using fluorescein isothiocyanate (FITC)-conjugated goat-antimouse IgG (Tago Inc, Burlingame, CA). For the transfected CHO-B7-1 cells, they were used at IO6 cells/mL and stained in a two-step procedure in the same manner as the T lymphocytes. For doublelabeling experiments, directly conjugated (phycoerythrin [PE]-labeled) primary MoAb against CD3 was used together with the appropriate blocking steps in connection with the indirect immunofluorescence staining as above for B7-1. Flow cytometric analysis was performed using a FACScan equipped with Lysis 2 software (Becton Dickinson, Mountainview, CA).
Imrnunostaining procedure. Five-micron thick cryostat sections of skin were immunostained using a sensitive avidin-biotin immunoperoxidase technique (Vectastain Kit, Vector Labs, Burlingame, CA), with 3-amino-4-ethyl carbazole as the chromogen producing a positive-red-reactive product as previously described.' For doublelabeling experiments a directly conjugated (PE-labeled) primary MoAb against CD28 was used together with appropriate blocking steps in conjunction with anti-B7-1 MoAb and FITC-conjugated goat-antimouse IgG as described above. An Olympus BH-2 fluorescence microscope equipped with both red and green filters was used to visualize the positively stained cell types.
T-cell activation. Polyclonal proliferation of resting PB T cells was induced using immobilized anti-CD3 MoAb (G19-4; gift of J. Ledbetter, Bristol Myers Squibb Pharmaceutical Corp) and IL-2 (100 U/mL; Boehringer-Mannheim, Indianapolis, IN) for 12 days in RPM1 1640 plus 10% FCS as previously described.'" For these experiments, 96-well round-bottom microtiter plates were coated with anti-CD3 MoAb as previously described? PB T cells before and after the stimulation were analyzed for HLA-DR expression and B7-1 expression by flow cytometry with the indicated reagents.
RESULTS
Immunostaining of cryostat sections of skin lesions for B7-I, CD28, and B7-3/BB-I. Because of the unexpected immunoreactivity of the lymphocytes with the B7 MoAb L307.4 as described below, we carefully tested the antigenic recognition capability of this MoAb. The object of this testing was to verify that the commercially obtained MoAb, L307.4, bound to the B7-1 molecule, and that the preparation was not contaminated with a second antibody that was reacting with the T cells. The anti-B7-l MoAb strongly reacted with CHO-B7-l transfected cells, but not controltransfected, B7-1 -negative C H 0 cells (Fig I) . Additionally, upon serial testing of the MoAb after sequential exposure to CHO-B7-1+ cells, flow cytometry showed that by four absorption cycles, the staining intensity of fresh CHO-B7-I positive cells was reduced to below isotype control, background levels (Fig 1) . Similar staining was observed for both lots of MoAb, L307.4, and the staining intensity diminished as the MoAb concentration was reduced from 10 pg/mL to 1 ,ug/mL; and was nonexistent at concentrations below 1 pg/ mL. Thus, we concluded that the MoAb was indeed recognizing an epitope exposed on the B7-1 molecule.
Immunostaining cryostat skin sections using this anti-B7-l MoAb showed that virtually all of the round lymphoid cells in both the epidermis and dermis of psoriatic and mycosis fungoides lesions were positive (Fig 2) . This staining pattern was observed for all biopsy specimens, and a representative example is shown in Figure 2A , which is a psoriatic plaque stained with anti-B7-1. Note the strong and diffuse staining of the round lymphoid cells in both epidermal and dermal compartments (Fig 2B) . The determination that these indicated cells are actually lymphocytes is based on their staining in serial sections for CD3 and either CD4 or CD8 (data not shown). The prominent accumulation of CD3+ T cells, but not B lymphocytes, in psoriatic plaques has been previously documented by several group^.'^ Staining of serial sections also showed that greater than 95% of the CD3+ cells in the psoriatic plaque were also CD28' as previously described' (data not shown). A double-stained cryostat section examined by fluorescence microscopy confirmed coexpression of B7-1 on the CD28+ T lymphocytes (Fig 2C) . When the CHO-B7-1 absorbed MoAb preparation was used, all immunoreactivity on the lymphocytes was abolished (data not shown). The ability of B7-l-absorption to abrogate T-cell immunoreactivity shows that the same antibody is binding both to recombinant B7-1 and to the T cell. The keratinocytes, endothelial cells, and dermal dendritic cells were B7-1-. An occasional epidermal Langerhans cell was B7-1+, as previous de~cribed.~ Staining the psoriatic lesions for B7-3BB-1 with anti-BB-l MoAb showed positive staining of basal and suprabasilar keratinocytes, but no staining of lymphoid cells (Fig 2D) . Figure 3A shows the B7-1 staining pattern of a representative mycosis fungoides lesion. Note the strong and diffuse staining of the lymphoid cells (identified as T cells by staining of serial sections with CD3, CD4, and CD8-data not shown) in both the dermis and epidermis including a large Pautrier microabscess. Staining of serial sections showed that the infiltrating lymphocytes diffusely expressed CD28 in both dermal and epidermal compartments, including the large Pautrier microabscess present in the epidermis ( Fig  3B) . When the CHO-B7 absorbed MoAb preparation was used, all immunoreactivity on the lymphocytes was abolished (data not shown). Staining mycosis fungoides lesions for B7-3BB-l showed strong positivity in the epidermis (particularly basal layer keratinocytes), but no staining of lymphocytes was observed (Fig 3C) .
Flow cytometric analysis ofpsoriatic lesional Tcells. TO
verify that the immunoreactivity for B7-1 on the T cells in these skin biopsies was not caused by a fixation artifact, lesional T cells were directly obtained from fresh unfixed keratome samples, and subjected to two-color immunofluorescence analysis by flow cytometry. The T cells could be separated from dermal dendritic cells by their forward and side-scatter properties (Fig 4A) . The exact nature of the round lymphoid cells was confirmed by their CD3 expression (Fig 4C) . These CD3' T cells were also positive for B7-1 using the MoAb L307.4 (Fig 4B) . Using the CHO-B7-l absorbed antibody, this B7-1 immunoreactivity was abolished (Fig 4D) . For the representative experiment shown in Fig 4, the mean fluorescent intensity on lesional T cells for the control MoAb was 2.4, and for B7-1 it was 26.7, yielding a B7-1:control ratio of 11: 1. Thus, specific B7-1 staining on lesional T cells was greater than l log above background.
Flow cytometric analysis of PB T cells. Resting PB T cells were HLA-DR-(data not shown), but expressed a low level of B7-1 that was consistently seen as only a slight shift of the fluorescence intensity over isotype control staining ( Fig  SA) . For example in Fig 5A, the mean fluorescent intensity on lesional T cells for the control MoAb was 19.6, and for B7-1 it was 61.6, yielding a B7-1:control ratio of only 3:l. Thus the amount of specific B7-l staining on PB T cells was significantly less than the values of 10 times above background seen for T cells isolated from psoriatic lesions (Fig   4) . After CHO-B7-1 absorption, this B7-1 immunoreactivity was diminished to near background levels. There was no increase in B7-1 expression observed when T cells were stimulated for 12 days on tissueculture plates coated with immobi- 
DISCUSSION
This report documents that virtually all lymphocytes in the dermis and epidermis of a benign (ie, psoriasis) and malignant (ie, mycosis fungoides) T-cell-mediated skin disease express B7-1, a CD28 ligand. These T cells also coexpress CD28 raising the interesting possibility of autocrine costimulation via B7-1:CD28 interaction. The antibody we used to identify B7-1, L307.4, was raised against B7-1-transfected cells (L. Lanier, personal communication, November 1993) , and is specific for B7-1; although the exact epitope on the B7-1 molecule that it recognizes has not been precisely identified. Nonetheless, we believe the MoAb is indeed recognizing a specific site on B7-1 based on the considerations above and on our own results absorbing the MoAb against CHO-B7-1+ cells.
Compared with PB T cells that only weakly express B7-1, the psoriatic and mycosis fungoides dermal T cells were more strongly B7-lf. Based on our current results, it appears that once the PB T cells enter the skin, there is accumulation of a subset that is expressing B7-1. At least two possible explanations for these results can be suggested: (1) local activation of a B7-1-T-cell population of a population that, initially, only weakly expresses B7-1, or (2) selective recruitment from the blood of an extremely low frequency (< 1 % of total T cells), and currently undetectable, subset of strongly B7-1+ T cells. With respect to the first possibility, because our in vitro stimulation experiments did not upregulate B7-1 on PB T cells, there may be other activation pathways for induction of B7-1 operative in vivo in these two skin diseases that are not being simulated by our in vitro protocol. Thus, based on the available data, we cannot definitely confirm either of the two aforementioned possibilities.
It should be mentioned that using this MoAb against B7-1, our results dealing with PB T cells have some similarities as well as differences with previous reports using different MoAbs against B7-1."." In contrast to these previous reports, we observed a low level of B7-I expression on resting PB T cells. However, after 12 days of stimulation no further increase was observed, which is in agreement with Sansom and Hall," but in disagreement with Azuma et al." Sansom and Hall required more than 30 days of stimulation before detection of B7-1 on PB T cells. We followed the stimulation protocol exactly as described by Azuma et al, and our only explanation for these differences is that the MoAbs used to detect B7-1 were different amongst each study. The finding of B7-1 on T cells in these two persistent dermatoses in vivo may reflect the fact that such lesional T cells have undergone chronic stimulation over several months.
Another important finding relates to the discordant expression of B7-1 versus B7-3/BB-1 on the T cells and keratinocytes. In the past, B7-1 and B7-3/BB-1 were thought to be identical antigens (termed B7/BB-1). However, we first described a discordant pattern of expression on activated keratinocytes in vitro and in vivo,' and the finding that these are distinct epitopes has since been confirmed by others.6 These current findings further confirm and extend the conclusion that B7 and BB-l are not identical antigens because the T cells express B7-1, but not B7-3BB-1; whereas the keratinocytes express B7-3BB-I , but not B7-1 immunoreactivity. It should be noted that the anti-B7-3/BB-I MoAb has cross-reactivity with B7-1 under certain circumstances, such as expression of the B7-1 gene in C H 0 cells. However, in our tissue sections (figures 2D and 3C) and in flow cytometry7 (data not shown), anti-B7-3/BB-1 MoAb stains keratinocytes but not T cells. It may not be possible to determine the cause of this phenomenon until the B7-3/BB-1 gene is further identified and/or cloned. However, it does suggest that reactivity with the anti-B7-3/BB-l MoAb might recognize a posttranslational modification of a protein product, For personal use only. on April 12, 2017. by guest www.bloodjournal.org From one which might not be made in T cells. Immunoprecipitation-based studies as well as efforts to clone the B7-3BB-1 gene are underway to definitively establish the identity of B7-3BB-1 and to permit direct comparison with the B7-1 gene product.
In conclusion, these results indicate that B7-1 (but not B7-3BB-1) is expressed by lymphocytes in two common and chronic skin disorders; one benign (psoriasis) and one malignant (mycosis fungoides). These lymphocytes also express CD28, and such cell-surface expression would theoretically permit a T cell to be able to undergo self-costimulation via interaction with B7-1. Such participation of costimulatory molecules may contribute to the ongoing T-cell proliferation that occurs in the skin of patients afflicted by these disorders.
